We build on our in-depth expertise in understanding post-translational modifications to develop medicines that modulate the activity and stability of proteins which are altered in disease settings. Our most advanced medicine in development, varoglutamstat, is an orally administered small molecule inhibitor of glutaminyl cyclases (QPCT and QPCTL), which are enzymes that modify certain proteins and peptides through a process known as pyroglutamate formation. This type of post-translational modification has been implicated in causing or promoting a number of diseases, including inflammatory and fibrotic diseases, neurodegenerative diseases, cancer and others.